Circulite, a company working out of Hackensack, New Jersey and Aachen, Germany, has announced an FIM (First in Man) of Synergy, its miniature heart pump designed to serve as a “partial circulatory support in patients with chronic heart failure”. Reportedly, the patient has already been discharged from the clinic and is doing well.
From the press release:
“The first implant of the Synergy device was very successful and the patient has already been discharged home and is doing very well,” said Prof. Meyns, Principal Investigator of the trial. “While CircuLite’s feasibility clinical study is in a bridge-to-transplant setting, the ultimate need for this type of device will be among those chronic heart failure patients who may not be eligible for a heart transplant. A partial support approach to chronic heart failure treatment may be better able to address the treatment needs and improve the quality of life for this unserved group of patients, who otherwise have no other options.”
News Image The CircuLite technology is designed to provide a new treatment option for over two million chronic heart failure patients worldwide who continue to be significantly symptomatic despite appropriate, optimal medical and device-based therapies. While feasibility studies will examine the hemodynamic and clinical effects of the Synergy device in patients that are awaiting heart transplants, CircuLite’s ultimate goal is to expand the treatment of heart failure to the chronic, ambulatory patient in order to improve their quality of life by giving them an elective, less-invasive option to increase blood flow from the heart.